Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Finished Goods (2019 - 2025)

CorMedix has reported Finished Goods over the past 5 years, most recently at $14.4 million for Q4 2025.

  • Quarterly results put Finished Goods at $14.4 million for Q4 2025, up 385.98% from a year ago — trailing twelve months through Dec 2025 was $14.4 million (up 385.98% YoY), and the annual figure for FY2025 was $14.4 million, up 385.98%.
  • Finished Goods reached $14.4 million in Q4 2025 per CRMD's latest filing, up from $12.8 million in the prior quarter.
  • Across five years, Finished Goods topped out at $14.4 million in Q4 2025 and bottomed at $245668.0 in Q2 2021.
  • Median Finished Goods over the past 3 years was $1.6 million (2024), compared with a mean of $3.9 million.
  • The largest annual shift saw Finished Goods crashed 39.79% in 2021 before it soared 1233.22% in 2025.
  • Over 3 years, Finished Goods stood at $245668.0 in 2021, then surged by 1105.29% to $3.0 million in 2024, then skyrocketed by 385.98% to $14.4 million in 2025.
  • Business Quant data shows Finished Goods for CRMD at $14.4 million in Q4 2025, $12.8 million in Q3 2025, and $3.3 million in Q2 2025.